← Leaderboards
Marwan Noel Sabbagh
Banner Sun Health Research Institute
$4,279,755
Attributed
$8,149,674
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2009–23$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,562,372 · 6
By mechanism
R01$7,421,745 · 3
P20$4,140,627 · 3
Top collaborators
- Boris Decourt9 shared
- Jeffrey R Wilson5 shared
- Yong Shen1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseClinical TrialsSafetyMild Cognitive ImpairmentMonitorClinical ResearchImpaired CognitionTnf GeneBrainTau ProteinsThalidomideTau-1NeuropathologyPharmaceutical PreparationsBloodStudy SubjectDesignPlacebosAmyloid Beta-ProteinImmunomodulatorsCognitionFda ApprovedNeuroinflammation
Grant awards (15)
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$701,731
R01 · FY2023 · AG · contact PI
Repurposing Siponimod for Alzheimer's Disease$687,290
R01 · FY2023 · AG · contact PI
Repurposing Siponimod for Alzheimer's Disease$688,670
R01 · FY2022 · AG · contact PI
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients$663,871
R01 · FY2022 · AG · contact PI
NVEADRC Administrative Core (AC)$354,903
P20 · FY2022 · AG · contact PI
Repurposing Siponimod for Alzheimer's Disease$731,856
R01 · FY2021 · AG · contact PI
Assessment of lenalidomide to treat Alzheimer's disease$639,729
R01 · FY2021 · AG · contact PI
Nevada Exploratory Alzheimer's Disease Research Center (NVEADRC)$1,149,763
P20 · FY2020 · AG · contact PI
Administrative Supplement for 1R01AG059008-01: Requested for investigational drug expenses$402,379
R01 · FY2020 · AG · contact PI
NVEADRC Administrative Core (AC)$373,026
P20 · FY2020 · AG · contact PI
COBRE GRANT$2,262,935
P20 · FY2019 · GM · contact PI
Assessment of lenalidomide to treat Alzheimer's disease$702,328
R01 · FY2019 · AG · contact PI
Assessment of lenalidomide to treat Alzheimer's disease$496,020
R01 · FY2018 · AG · contact PI
Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease$839,712
R01 · FY2010 · AG · contact PI
Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease$868,159
R01 · FY2009 · AG